Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Fengbei Biotech Stock Co (SHSE:603334) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Suzhou Fengbei Biotech Stock Co Cash Conversion Cycle Related Terms
Suzhou Fengbei Biotech Stock Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Fengbei Biotech Stock Co Cash Conversion Cycle Chart
SHSE:603334 vs WM, RSG, WCN: Cash Conversion Cycle Comparison
For the Waste Management subindustry, Suzhou Fengbei Biotech Stock Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Fengbei Biotech Stock Co Cash Conversion Cycle vs Waste Management Industry
For the Waste Management industry and Industrials sector, Suzhou Fengbei Biotech Stock Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Suzhou Fengbei Biotech Stock Co's Cash Conversion Cycle falls into.
Suzhou Fengbei Biotech Stock Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Fengbei Biotech Stock Co (SHSE:603334) has a Cash Conversion Cycle of 41.54 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Suzhou Fengbei Biotech Stock Co and its competitors.
Is Suzhou Fengbei Biotech Stock Co's Cash Conversion Cycle too high?
Suzhou Fengbei Biotech Stock Co's current Cash Conversion Cycle is 41.54. The Waste Management industry median Cash Conversion Cycle is 48.54. Suzhou Fengbei Biotech Stock Co's value of 41.54 is 14.4% below this industry median. Overall, Suzhou Fengbei Biotech Stock Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Suzhou Fengbei Biotech Stock Co's Cash Conversion Cycle compare to WM and RSG?
Suzhou Fengbei Biotech Stock Co's Cash Conversion Cycle of 41.54 can be compared against companies in the Waste Management industry. The industry median Cash Conversion Cycle is 48.54. Suzhou Fengbei Biotech Stock Co's value of 41.54 is 14.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Waste Management company?
The median Cash Conversion Cycle among Waste Management companies is 48.54, based on 236 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Fengbei Biotech Stock Co's current Cash Conversion Cycle of 41.54 is 14.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Suzhou Fengbei Biotech Stock Co and its competitors. For the Waste Management industry, the median Cash Conversion Cycle is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Fengbei Biotech Stock Co's current Cash Conversion Cycle is 41.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Fengbei Biotech Stock Co stock overvalued right now?
Suzhou Fengbei Biotech Stock Co (SHSE:603334) has a current Cash Conversion Cycle of 41.54. The current Cash Conversion Cycle is 41.54 and 14.4% below the Waste Management industry median of 48.54. Suzhou Fengbei Biotech Stock Co's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Suzhou Fengbei Biotech Stock Co (SHSE:603334), the current Cash Conversion Cycle is 41.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Suzhou Fengbei Biotech Stock Co Business Description
Suzhou Fengbei Biotech Stock Co Ltd is focused on the comprehensive utilization of waste oil and fat resources. The company is engaged in the research and development, production, and sales of industrial packaging materials, methyl oleate, and methylated soybean oil (excluding food products). It operates as an independent import and export agent for various commodities and technologies. The company's licensed projects include Fertilizer production, and General projects include Technical services, technical development, technical consultation, technical exchange, technology transfer, and technology promotion. It is into the research and development of bio-organic fertilizers, compound microbial fertilizers, and bio-pesticide technology.
40GF Score
Get the complete analysis for SHSE:603334
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603334 has been successfully added to your 
